Hydroxyurea Pharmacokinetic Evaluation in Patients with Sickle Cell Disease

Hydroxyurea Pharmacokinetic Evaluation in Patients with Sickle Cell Disease

<b>Background:</b> Hydroxyurea (HU), also known as hydroxycarbamide, is an oral ribonucleotide reductase inhibitor. In 1999, the United States Food and Drug Administration (FDA) approved HU for the treatment of sickle cell disease (SCD). Since then, it has become the cornerstone in the m...

Full description

Saved in:
Bibliographic Details
Main Authors: Daniela Di Grazia (Author), Cristina Mirabella (Author), Francesco Chiara (Author), Maura Caudana (Author), Francesco Maximillian Anthony Shelton Agar (Author), Marina Zanatta (Author), Sarah Allegra (Author), Jenni Bertello (Author), Vincenzo Voi (Author), Giovanni Battista Ferrero (Author), Giuliana Abbadessa (Author), Silvia De Francia (Author)
Format: Book
Published: MDPI AG, 2024-10-01T00:00:00Z.
Subjects:
article
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

Connect to this object online.

3rd Floor Main Library

Holdings details from 3rd Floor Main Library
Call Number: A1234.567
Copy 1 Available

Similar Items